Brensocatib

Brensocatib is an investigational new drug that is being evaluated to treat bronchiectasis.^[1] It is a dipeptidyl-peptidase I (also known as cathepsin C) inhibitor.^[2]

Brensocatib

Clinical data
Other names	AZD7986; INS1007
Identifiers
IUPAC name (2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide
CAS Number	1802148-05-5
PubChem CID	118253852
IUPHAR/BPS	9412
DrugBank	DB15638
ChemSpider	67896269
UNII	25CG88L0BB
KEGG	D12120
ChEMBL	ChEMBL3900409
Chemical and physical data
Formula	C23H24N4O4
Molar mass	420.469 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)OC1=O
InChI InChI=1S/C23H24N4O4/c1-27-19-12-17(7-8-20(19)31-23(27)29)16-5-3-15(4-6-16)11-18(13-24)26-22(28)21-14-25-9-2-10-30-21/h3-8,12,18,21,25H,2,9-11,14H2,1H3,(H,26,28)/t18-,21-/m0/s1 Key:AEXFXNFMSAAELR-RXVVDRJESA-N

A phase 3 clinical trial, known as the ASPEN trial, was conducted to evaluate the safety and efficacy of brensocatib in patients with non-cystic fibrosis bronchiectasis.^[3] Brensocatib tablets (Brinsupri) by Insmed Inc. was approved by the FDA in August 2025 after it received breakthrough therapy designation and was reviewed on a priority timeline.